15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Adapthealth Corp, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $8.00 to $16.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $11.86 sits 92% above the current $6.18. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 7 over recent months. On the fundamentals, the Street sees revenue growth near 7% this year and 6% next, consensus EPS building from about $-0.06 next quarter toward $-0.13 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Adapthealth Corp.
As of Sep, 7 of 7 firms rate AHCO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AHCO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.12 – $-0.01 · 5 analysts · -121% YoY
Next period, 5 analysts expect Adapthealth Corp to earn $-0.06 a share (range $-0.12 – $-0.01), versus $0.27 a year earlier. Full-year consensus is $-0.45, growing to $-0.13 the year after.
REVENUE · NEXT QUARTER
$731.1M
Range $715.1M – $744.4M · 5 analysts · +8% YoY
Revenue is expected to reach $731.1M (range $715.1M – $744.4M), +8.0% year-over-year. Full-year consensus is $2.9B, rising to $3.0B next year.
Top analysts covering Adapthealth Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AHCO.
#1
DM
David Macdonald
Truist Securities · Rank #109
Buy
$9.00+45.5% to target
Overall win rate
48%
+ Follow
#2
Ben Hendrix
RBC Capital · Rank #149
Buy
$8.00+29.3% to target
Overall win rate
44%
+ Follow
#3
Brian Tanquilut
Jefferies · Rank #208
Buy
$13.00+110.2% to target
Overall win rate
42%
+ Follow
#4
Kevin Caliendo
UBS
Buy
$10.00+61.7% to target
Coverage
—
+ Follow
#5
EC
Eric Coldwell
Baird
Buy
$10.00+61.7% to target
Coverage
—
+ Follow
AHCO stock forecast FAQ
What is AHCO's average 12-month price target?+
The 7 analysts with a live target average $11.86 for Adapthealth Corp over the next 12 months, ranging from a $16.00 high to a $8.00 low.
Is AHCO stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AHCO?+
The Street-high target is $16.00 (Canaccord Genuity), and the Street-low is $8.00 (RBC Capital). The average of all 7 active targets is $11.86.
How many Wall Street analysts cover AHCO?+
7 analysts have an active rating on Adapthealth Corp, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering AHCO?+
Among analysts who currently cover AHCO, David Macdonald of Truist Securities has the strongest overall Quantellect track record (Rank #109). Their current call is Buy with a $9.00 target.
What is Adapthealth Corp's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.12 – $-0.01) across 5 analysts. Full-year EPS is projected at $-0.45, rising to $-0.13 the following year.
How much revenue is Adapthealth Corp expected to report next quarter?+
Consensus revenue is $731.1M (range $715.1M – $744.4M). Full-year revenue is projected at $2.9B, growing to $3.0B next year.
Have analysts been upgrading or downgrading AHCO lately?+
As of Sep, 7 of 7 firms rate AHCO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AHCO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
